PharmAla Issues Audited Year End 2025 and Unaudited Q1 Fiscal 2026 Financial Statements
(CNSX:MDMA.CN),(CNSX:MDMA),(OTC US:MDXXF),(Other OTC:MDXXF), TORONTO, Dec. 24, 2025 (GLOBE NEWSWIRE) — PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company“) (CSE: MDMA) (OTC: MDXXF), a biotechnology company focused on the research, development, and manufacturing of LaNeo(TM) MDMA and novel derivatives of MDMA (MDXX class molecules), is pleased to have publicly filed its financial results for the periods […]